Oncotarget is an informative journal published mainly about oncology – the scientific study of tumors and their treatment. The journal was first published in 2010 and has made a great impact since then. Its chief editors are Andrei V. Gudkov of Rosswell Park Cancer Institute and Mikhail Blagosklonny. With a company size of 11-50 employees, the privately owned medical journal has its headquarters based in East Quaker Street, US. This multidisciplinary journal is published by Impact Media.
The Road to Success
Oncotarget has made an average impact of about 5.168 since 2010 all the way to 2016. Oncotarget started as a weekly journal but due to the rise of its impact and demand, it is now published twice a week – on Tuesday and Friday. The increase in its popularity is due to its multi-peer review and constructive research results it offers through its authors and more
Oncotarget is leading in journal ranking with the highest number of documents covering oncology. It has become successful and is now covering other medical areas besides oncology. These fields include neuroscience, cell death, microbiology, autophagy, neurotarget, immunology, pathology, aging, and circadian rhythm. The types of articles covered are research papers, news and editorials, reviews, books, and super reviews.
The Mission of Oncotarget
The aim of the journal is to rapidly and widely avail results of medical researches to readers. This help by saving time spent during research and offering new information on exceptional discoveries. It also offers an insightful review which ensures the research makes a great impact.
The journal offers free access which means the ownership of the copyright remains under the author but readers are free to download, modify, print, distribute, reuse or copy the articles. This ensures that the multidisciplinary research results are available to the public freely, maximizing their impact. Everyone desires a life without ailments. This journal helps scientists apply basic science in controlling diseases. It also allows all researchers to take part in the progression of science.